University of Ljubljana, Faculty of Medicine, Institute of Microbiology and Immunology, Zaloška 4, 1105 Ljubljana, Slovenia.
Expert Rev Anti Infect Ther. 2010 Oct;8(10):1139-62. doi: 10.1586/eri.10.104.
Five main groups of commercial assays for the multiplex detection of alpha human papillomaviruses (HPVs) are currently available. DNA-based screening assays, which test for the presence of 13-14 HPVs without determination of HPV type, have been the standard for HPV detection in the last decade. Assays that combine testing for 14 HPVs and HPV-16 and HPV-18 genotyping are a potential future standard for HPV detection. The clinical value of HPV genotyping assays has still not been finally determined. Recently, one of the mRNA-based assays showed equal clinical sensitivity but higher clinical specificity for CIN2+/CIN3+ in comparison with the validated DNA-based assay. In situ hybridization assays are too laborious and have insufficient clinical sensitivity to be used in routine screening. Automation, price reduction and improvement of clinical specificity are the main goals for the future development of HPV assays.
目前有五种主要的商业化多重检测人乳头瘤病毒（HPV）的试剂盒。在过去十年中，基于 DNA 的筛查检测方法一直是 HPV 检测的标准，该方法检测 13-14 种 HPV 的存在情况，但无法确定 HPV 类型。将 14 种 HPV 检测与 HPV-16 和 HPV-18 基因分型相结合的检测方法可能成为 HPV 检测的未来标准。HPV 基因分型检测的临床价值尚未最终确定。最近，一种基于 mRNA 的检测方法在比较 CIN2+/CIN3+时，其临床敏感性与经过验证的基于 DNA 的检测方法相同，但临床特异性更高。原位杂交检测方法过于繁琐，临床敏感性不足，无法用于常规筛查。自动化、降低价格和提高临床特异性是 HPV 检测未来发展的主要目标。
